Cell and Gene Therapy Catapult (CGT Catapult) announced GSK will leverage the CGT Catapult Stevenage facility to perform GMP cell processing to accelerate its cell and gene therapy pipeline for clinical trials. Through this agreement, GSK will improve its GMP cell processing network to advance its early-stage pipeline and streamline technical transfer.
“The UK already has significant capabilities in cell and gene therapy, and this agreement illustrates how strategic investments by GSK can make them even stronger. Working more closely with CGT Catapult will help us advance our promising cell and gene therapy programs, and bring these transformative medicines more quickly to the patients who desperately need them,” Tony Wood, Senior Vice President, Medicinal Science and Technology of GSK said.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!
“The move by a leading pharmaceutical company like GSK to establish ATMP manufacturing capabilities at the CGT Catapult facility in Stevenage highlights the UK’s globally leading position for large and smaller organizations alike to develop, manufacture and deliver cell and gene therapies. With a range of collaborators already based in the facility, we look forward to participating in the collective innovation onsite to pioneer the growth in scale of advanced therapy manufacturing,” Matthew Durdy, Chief Executive Officer of Cell and Gene Therapy Catapult said.